AI Bias Analysis
4 models · Takes ~15 seconds
Sanofi asked the FDA to pull teplizumab out of a speedy review voucher program after a political appointee disagreed with staff over its approval
Source
Stat News
Opens original article in a new tab
The hantavirus outbreak on the MV Hondius has focused the public's attention on cruise ship safety.
(MedPage Today) -- An investigational mRNA-based vaccine against three strains of influenza outperformed standard flu shots among adults ages 50 and older in the Fluent randomized trial. Reverse transcriptase-polymerase chain reaction-confirmed...
A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.
(MedPage Today) -- The FDA expanded the approval of ustekinumab (Stelara) in Crohn's disease to include the treatment of kids as young as 2 years, Johnson & Johnson announced. High clinical remission rates (98%) at approximately 5 years were...
